Implementation of Quality by Design in the Formulation and Development of Nanocarrier-Based Drug Delivery Systems
-
Published:2023
Issue:3
Volume:40
Page:1-46
-
ISSN:0743-4863
-
Container-title:Critical Reviews™ in Therapeutic Drug Carrier Systems
-
language:en
-
Short-container-title:Crit Rev Ther Drug Carrier Syst
Author:
Mehrotra Sonal,Salwa ,Kumar Lalit
Abstract
Quality by design (QbD) has recently fascinated researchers for utilizing it in various arenas of pharma trends. By overcoming the conventional process, QbD prevents the risk of errors caused by the 'guess and by god approach'. This framework fosters profound knowledge of product and process quality by implying sound science and risk assessment strategies. The virtue of QbD leads to the collaborative contribution to pharmaceutical industrialists and satisfies the regulatory bodies. Additionally, leading to rapid production, saves time and expenditure, tremendous versatility, provides immense knowledge, improves robustness, higher consistency, reduces user's dilemma, decreases certainty of failure, declining inter-batch variation in pharmaceutical development. In this ever-increasing continuous production world, regulatory organizations such as the U.S. Food & Drug Administration and the International Conference on Harmonization recommend Q8 to Q14 guidelines in order to obtain the desired quality product. This review extensively discusses on various approaches of QbD for the pharmaceutical development of nano-carrier drug delivery systems. Additionally, QbD's applications in process and analytical method development techniques are documented.
Reference151 articles.
1. Newton PN, Green MD, Fernandez FM. Impact of poor-quality medicines in the 'developing' world. Trends Pharmacol Sci. 2010;31:99-101. 2. Schulman KA. Challenges in ensuring the quality of generic medicines. Health Aff. 2020;39:1643-6. 3. Pegler S, Underhill J. Evaluating the safety and effectiveness of new drugs. Am Fam Physician. 2010;82:53-7. 4. Godman B, Bucsics A, Bonanno P V, Oortwijn W, Rothe CC, Ferrario A, Bosselli S, Hill A, Martin AP, Simoens S, Kurdi A, Gad M, Gulbinovic J, Timoney A, Bochenek T, Salem A, Hoxha I, Sauermann R, Massele A, Guerra AA Jr, Petrova G, Mitkova Z, Achniotou G, Laius O, Sermet C, Selke G, Kourafalos V, Yfantopoulos J, Magnusson E, Joppi R, Oluka M, Kwon HY, Jakupi A, Kalemeera F, Fadare JO, Melien O, Pomorski M, Wladysiuk M, Markovic-Pekovic V, Mardare I, Meshkov D, Novakovic T, Furst J, Tomek D, Zara C, Diogene E, Meyer JC, Malmstrom R, Wettermark B, Matsebula Z, Campbell S, Haycox A. Barriers for access to new medicines: Searching for the balance between rising costs and limited budgets. Public Health Front. 2018;6:328. 5. Juran JM. Juran on quality by design: The new steps for planning quality into goods and services. 1st ed. Spain: Free Press; 1992. p. 538.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|